The highly optimized transTACs (with variations in the binding domains and linkers) were first designed to bind to TfR1 and CD19 chimeric antigen receptors (CARs) expressed on Jurkat or HeLa cancer cells and led to an up to 80% POI degradation. The gene discussed is TFRC; the disease is cancer.